Sound Bioventures

Our expertise in biopharma and biotech investments. With decades of experience and a robust network within the biopharma and biotech industries, our team offers unparalleled insight into the scientific and financial landscapes. We are dedicated to identifying transformative therapies and supporting companies that are pioneering the future of healthcare. Empowering entrepeneurs to build leading companies Biovance Capital works closely with entrepreneurs to build leading companies with transformative treatments for patients in need. Stage: We invest in early-stage companies at seed and Series A rounds across Europe, with a focus in Southern countries. Technology: We invest in biotech companies developing therapeutics in any modality and therapeutic area. We require robust and appropriate preclinical models and patented or patentable assets before investing. Market: Large target market with a clear regulatory pathway for approval, with favorable reimbursement and pricing policies. Exit Potential: Sectors with VC/M&A or IPO activity, featuring profitable exits and multiple potential acquirers. Sustainability: During the due diligence process, sustainability risks are taken into account, and whenever identified, mitigation measures are proposed.

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

Trinity Innovation Bioventure Singapore is a licensed biomed venture capital fund focusing on innovation and value investment with deep insight and experience on Asia markets. We are part of the Trinity Innovation Fund group, founded in 2018, managing multiple VC funds in the region. We are an experienced team led by industrial veterans who have managed multiple VC funds and invested over dozens of biotech companies. Our StrengthAccess to China market through synergy with TIF: Two organizations, One Team Multi-dimensional value-added post investment to enhance possibility of success and returns Clear investment thesis: In Asia, for Global; Leverage regional synergy and realize future value Best-in-class team in biomed investment with strong track record Our Focus TIBS seeks to invest and build great companies that emerging biotechnology leads to innovative therapeutics to address global unmet medical needs. We focus on incubating and growing potential early-stage biotech start-ups with breakthrough platform technology, differentiated scientific merit and commercial value. Our Core CompetencyValue Discovery: Select investment projects based on precise judgements from in-depth research Project Incubation: Incubate cutting-edge science or outstanding entrepreneurs with innovative approaches. Unique incubation strategy: project management by investment team to increase the asset value; management team recruitment to maximize the equity value and capital efficiency Help entrepreneurs to grow rapidly with proprietary foresight, industry understanding and resources

Curie.Bio is a unique combination of two businesses: we act as both your drug discovery copilot & seed investor. We have some of the world’s best drug hunters, drug makers, experts, and vendors supporting our founders to increase their chances of developing successful medicines. By support, we don’t mean just a couple of hours a month. We are in the trenches with you on a day-to-day basis operating as fully integrated members of your team. We help you choose therapeutic targets, set milestones based on investor feedback, and design experimental plans. We interview and select drug discovery vendors to enable you to hit those milestones. We help identify what expertise needs to be brought in to support your key programs and then get you the right experts. We evaluate incremental data readouts with you to help determine which experiments need to be adjusted from the initial plan. We do real work. When you’re ready for your Series A, we work with you end-to-end on your data room, deck, and pitch. We make investor intros and coach you on how to run an excellent fundraising process to optimize the quality of your round. Curie.Bio’s model gives you a higher chance of success & reduces future dilution. How? By working with us, you make significant progress on your lead program(s) while being extremely capital efficient. We provide real help designing and executing your seed plan, including navigating the bumps, twists, and turns all along the way. This progress leads to better terms when raising a Series A & Series B. Investors now have a clear line of sight to getting your lead program(s) into the clinic. Post Curie.Bio’s seed, founders are positioned to raise significant capital to advance their programs without giving up as much future equity in their company. Simply put: better planning and more progress at the seed means a significantly higher chance of a future where you retain control, upside, and agency over your own company. Why us?Our team has brought over 60 drugs into the clinic with 12 approvals. Our team has founded biotech companies with more than $30 billion in enterprise value. We aim to bring our decades of experience to founders across the globe and have raised over $500m to make our vision a reality. We started with a problem statement: you can’t start a therapeutics company in your garage. Drug discovery is an incredibly complex process with multiple points of failure, particularly in the earliest stages of building a new company. We’re launching with a big idea: if we can help founders avoid mistakes, ensure they have the right data, plan & story, all while retaining the incentive to build their own company, we could in essence, free the founders. We believe the single greatest unlock of innovation in biotech over the next decade will come from creating more founders – more risk takers – more scientists with phenomenal ideas who have the support they need to start their own company.

Our primary focus is on the development of novel therapeutics and platforms. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. Invest Globally: We invest in North America, Europe and Israel with approximately USD 750 million under management in committed capital. We continue our strategy of making larger focused investments and anticipate total investments up to USD 30 million per company over its life. Invest Across Healthcare Sector: We make equity investments in Biotechnology/Biopharma life sciences companies. NVF is stage agnostic and engages in seed investments as well as later-stage investments. We typically lead or co-lead an investment and play an active role on company boards.

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.